DEVELOPMENT AND VALIDATION OF NOVEL RP-HPLC-DAD METHOD FOR QUANTIFICATION OF LAPATINIB DITOSYLATE IN NEWER NANO-LIPOSOME FORMULATION: A QUALITY BY DESIGN (QBD) APPROACH

Authors

DOI:

https://doi.org/10.22159/ijap.2022v14i6.45750

Keywords:

RP-HPLC, Quality by Design, Validation, Lapatinib ditosylate, Liposome

Abstract

Objective: The current study entails quality by design (QbD) enabled the development of a simple, rapid, sensitive, and cost-effective RP-HPLC method for estimation of Lapatinib ditosylate (LPT) in a newly prepared nano-liposomal formulation which has not been reported earlier.

Methods: The chromatographic factors were screened using a fractional factorial design. A central composite design was employed as a response surface methodology. Mobile phase ratio, flow rate, and wavelength were identified as critical method parameters. To minimize retention time, peak area, and theoretical plates were employed as critical analytical attributes. A novel nano-liposomal formulation of LPT was prepared by the film hydration method. 

Results: The optimized chromatographic condition was obtained at a mobile phase composition of methanol and 0.05% v/v o-phosphoric acid in water (81:19 v/v), flow rate 0.7ml/min, and peak detected at wavelength 261 nm using DAD detector. The retention time for Lapatinib was 3.702min. The developed method was validated as per ICH guidelines ICH Q2 (R1). Linearity (R2= 0.999) was observed in the range of 10-50μg/ml. The limit of detection and limit of quantitation was found to be 0.6309μg/ml and 1.9120μg/ml respectively. LPT containing liposome formulation assay was found to be 99.03% and %RSD was less than 1%.

Conclusion: The newly developed RP-HPLC method applying the QbD approach was found to be simple, specific, precise, accurate, linear, and rugged with good recovery of LPT in the nano-liposome formulation in a cost-effective manner. Hence it can be employed for the quantification of LPT in bulk and pharmaceutical formulations.

Downloads

Download data is not yet available.

References

Beg S, Sharma G, Katare OP, Lohan S, Singh B. Development and validation of stability-indicating liquid chromatographic method for estimating Olmesartan, Medoxomil using quality by design. Journal of Chromatographic Science. 2015; 53(7): 1048-59.

The International Conference on Harmonization ICH Technical Requirements for Registration of Pharmaceuticals for Human Use on Pharmaceutical Development Q8(R2); 2009. https://database.ich.org/sites/default/files/Q8%2 8R2%29%20Guideline.pdf

The International Conference on Harmonization ICH Technical Requirements for Registration of Pharmaceuticals for Human Use on Quality Risk Management Q9; 2005. https://database.ich.org/sites/default/files/Q9%20Guideline.pdf

The International Conference on Harmonization ICH Technical Requirements for Registration of Pharmaceuticals for Human Use on Pharmaceutical Quality System Q10; 2008. https://database.ich.org/sites/default/files/Q10%20Guideline.pdf

Borman P, Nethercote P, Chatfield M, Thompson D, Truman K. The application of quality by design to analytical methods. Pharm Tech. 2007; 31: 142-52.

Schweitzer M, Pohl M, Hanna BM, Nethercote P, Borman P, Hansen G. Implications and opportunities of applying QbD principles to analytical measurements. Pharm Tech. 2010; 34: 52-9.

Galen WE, Analytical Instrumentation Handbook, 2nd ed. Marcel Dekker Inc, New York; 2004.

Snyder L, Kirkland J, Glajch L. Practical HPLC method development; 2nd ed. John Wiley & Sons Inc, New York; 1997. https://doi.org/10.1002/978111 8592014

Bossunia M, Urmi K, Chironjit Kumar S. Quality-By-Design approach to stability indicating RP-HPLC analytical method development for estimation of Canagliflozin API and its validation. Pharmaceutical Methods Pharmaceutical Biology. 2017; 8(2): 92-101.

Sandhu P, Beg S, Katare P, Singh B. QbD-driven development and validation of a HPLC method for estimation of Tamoxifen citrate with improved performance. Journal of chromatographic science. 2016; 54(8): 1373-84.

Mondal S, Biswal S, Acharya T, Mondal P, Bhar K. Determination of LPT in bulk and tablet dosage form using ultraviolet spectrophotometric and RP-HPLC analytical methods. International Journal of Pharmaceutical Investigation. 2021; 11(2): 208-13.

Kumar K, Nagoji K, Nadh R. A validated RP-HPLC method for the estimation of LPT in tablet dosage form using Gemcitabine hydrochloride as an internal standard. Indian Journal of Pharmaceutical Sciences. 2012; 74(6): 580.

Haribabu B, BalaMurali KK, Rama KP. Development and validation of HPLC method for the estimation of Lapatinib in bulk drugs and pharmaceutical formulations. Int J Res Rev Pharm Appl Sci. 2011; 1: 207-14.

Reehana SK, Sujana K. LC-MS/MS Characterization of forced degradation products of Tucatinib, a novel tyrosine kinase inhibitor: development and validation of RP-HPLC Method. Int J App Pharm. 2022; 14(1): 58-66.

Palnati N, Kotapati N, Vaidyanathan G. Liquid chromatography–mass spectrometry/mass spectrometry method for the determination of Lapatinib in rat plasma: application to pharmacokinetic studies in wistar rats. Asian J Pharm Clin Res. 2021; 14(2): 74-7.

Bai F, Freeman BB 3rd, Fraga CH, Fouladi M, Stewart CF. Determination of Lapatinib (GW572016) in human plasma by liquid chromatography electrospray tandem mass spectrometry (LC-ESI-MS-MS). 2006; 831: 169-75.

Haouala A, Zanolari B, Rochat B, Montemurro M, Zaman K, Duchosal MA. Therapeutic Drug Monitoring of the new targeted anticancer agents Imatinib, Nilotinib, Dasatinib, Sunitinib, Sorafenib and Lapatinib by LC tandem mass spectrometry. 2009; 877: 1982-96.

Sandra R, Gillian McM, Martin C, Robert OC. Development and application of novel analytical methods for molecularly targeted cancer therapeutics. J Chromatogr B. 2009; 877: 3982-90.

Götze L, Hegele A, Metzelder SK, Renz H, Nockher WA. Development and clinical application of a LC-MS/MS method for simultaneous determination of various tyrosine kinase inhibitors in human plasma. Clin Chim Acta. 2012; 413: 143-49.

Couchman L, Birch M, Ireland R, Corrigan A, Wickramasinghe S, Josephs D. An automated method for the measurement of a range of tyrosine kinase inhibitors in human plasma or serum using turbulent flow liquid chromatography-tandem mass spectrometry. Anal Bioanal Chem. 2012; 403: 1685-95.

Bouchet S, Chauzit E, Ducint D, Castaing N, CanalRaffin M, Moore N. Simultaneous determination of nine tyrosine kinase inhibitors by 96-well solid-phase extraction and ultra-performance LC/ MS-MS. Clin Chim Acta. 2011; 412: 1060-67.

Rakic T, Vujanovic I, Jovanovic M, Stojanovic B, Ivanovic D. Comparison of full factorial design, central composite design, and Box-Behnken design in chromatographic method development for the determination of Fluconazole and its impurities. Anal Lett. 2014; 47(8): 1334-47.

Bezerra M, Santelli R, Oliveira E, Villar L, Escaleira L. Response surface methodology (RSM) as a tool for optimization in analytical chemistry. Talanta. 2008; 76(5): 965-77.

Narahari P, Vijayaraj S, Lathasri K, Archana D, Rajavel P. Chemometric approach to develop and validate RP-HPLC method for estimation of Erlotinib hydrochloride in nano structured lipid carriers. Current Pharmaceutical Analysis. 2019; 15: 1-6.

Ferreira SLC, Caires AO, Borges TdaS, Lima AMDS, Silva LOB, dos Santos WNL. Robustness evaluation in analytical methods optimized using experimental designs. Microchemical Journal. 2017; 131: 163-69. https://doi.org:10.1016/j.microc.2016.12.004

Shrivastava R, Trivedi S, Singh PK, Asif M, Chourasia MK, Khanna A, et al. Design and development of PEGylated liposomal formulation of HER2 blocker Lapatinib for enhanced anticancer activity and diminished cardiotoxicity. Biochem Biophys Res Commun. 2018; 503(2): 677–83.

Charumathy A, Ubaidulla U, Sinha P, Rathnam G. Recent update on liposome-based drug delivery system. Int J Curr Pharm Res. 2022; 14(3): 22-7.

Kumar KK, Nagoji KEV, Nadh RV. Validated RP-HPLC method for the estimation of Lapatinib in tablet dosage form using Gemcitabine hydrochloride as an internal standard, Indian J Pharm Sci. 2012, 74 (6): 580-83.

Singh B, Kumar R, Ahuja N. Optimizing drug delivery systems using systematic design of experiments. Part I: fundamental aspects. Critical Reviews™ in Therapeutic Drug Carrier Systems. 2005; 22(1): 27-105.

Beg S, Chaudhary V, Sharma G, Garg B, Panda SS, Singh B. QbD‐oriented development and validation of a bioanalytical method for Nevirapine with enhanced liquid–liquid extraction and chromatographic separation. Biomedical Chromatography. 2016; 30(6): 818-28.

Merey HA, Galal MM, Salem MY, Abdel-Moety EM. Novel stability indicating methods for the determination of certain synthetic Estrogen level modifiers. Bulletin of Faculty of Pharmacy, Cairo University. 2013; 51(1): 69-79.

Bhoop BS, Beg S, Raza K. Developing “optimized” drug products employing “designed” experiments. Chemical Industry Digest. 2013; 23: 70-6.

Kaur R, Saini S, Sharma T, Katare OP, Kaushik A, Singh B. Implementation of analytical Quality-by-Design for developing a robust HPLC method for quantitative estimation of Voriconazole: Application in drug formulations. Analytical Chemistry Letters. 2021; 11(2): 168-86.

Sandhu PS, Beg S, Katare OP, Singh B. QbD-driven development and validation of a HPLC method for estimation of Tamoxifen citrate with improved performance. Journal of Chromatographic Science. 2016; 54(8): 1373-84.

IHT Guideline. Validation of analytical procedures: text and methodology Q2 (R1); 2005. http://www. Ich.org/cache/compo/ 363-272-1 html, (2010)

Shimek JL, Rao N, Khalil SW. High performance liquid chromatographic analysis of Tolmetin, Indomethacin and Sulindac in plasma. Journal of Liquid Chromatography, 1981; 4: 1987–2013.

Muller IB, Windberg CN. Validation of an HPLC method for quantitation of MDMA in tablets. Journal of Chromatographic Science. 2005; 43: 434–37.

Vander HY, Nijhuis A, Smeyers-Verbeke J, Vandeginste B, Massart D. Guidance for robustness/ruggedness tests in method validation. Journal of Pharmaceutical and Biomedical Analysis. 2001; 24: 723-53.

Shabir GA. Validation of high-performance liquid chromatography methods for pharmaceutical analysis: Understanding the differences and similarities between validation requirements of the US Food and Drug Administration, the US Pharmacopeia and the International Conference on Harmonization. Journal of Chromatography A. 2003; 987: 57-66.

Ebrahim S, Pooya DK, Fatemeh R, Farzad K, Farid AD. Development and validation of rapid stability-indicating RP-HPLC-DAD method for the quantification of Lapatinib and mass spectrometry analysis of degraded products. Journal of Chromatographic Science. 2015; 53: 932-9.

Panda SS, Bera RKVV, Behera AK, Beg S. Chemometrics assisted development of a liquid chromatography method for estimation of Lapatinib in tablets: A case study on a novel quality concept. Sep Sci plus. 2019;1–10.

Saadat E, Ravar F, Dehghankelishadi P, Dorkoosh FA. Development and validation of a rapid RP-HPLC-DAD analysis method for the simultaneous quantitation of Paclitaxel and Lapatinib in a polymeric micelle formulation. Sci Pharm. 2016; 84(2): 333-45.

Alrobaian M, Panda SS, Almalki WH, Afzal O, Kazmi I, Alossaimi MA, Al-Abbasi FA, Katouah HA, Rub RA, Ravi Kumar BV, Rahman M, Beg S. Development and validation of chemometrics-assisted green UPLC-MS/MS bioanalytical method for simultaneous estimation of Capecitabine and Lapatinib in rat plasma. Journal of Chromatographic Science, 2022; 60(6): 559–70.

Published

02-09-2022

How to Cite

SONAR, P., SHAIKH, K., & HARER, S. (2022). DEVELOPMENT AND VALIDATION OF NOVEL RP-HPLC-DAD METHOD FOR QUANTIFICATION OF LAPATINIB DITOSYLATE IN NEWER NANO-LIPOSOME FORMULATION: A QUALITY BY DESIGN (QBD) APPROACH. International Journal of Applied Pharmaceutics, 14(6). https://doi.org/10.22159/ijap.2022v14i6.45750

Issue

Section

Original Article(s)